Abstract
Recent advances in genetics have revolutionized our understanding of dementia. In the most common of the human dementing illnesses-Alzheimer s disease (AD)- mutations in three major genes causing rare dominantly inherited AD (APP, PS1 and PS2), and other contributory genetic risk factors, such as APOE have been identified. Although neurofibrillary tangles composed of tau protein filaments are a diagnostic feature of AD, tau mutations have not been described in AD. Frontotemporal dementia (FTD) encompasses a group of non-Alzheimers degenerative dementias affecting mainly the frontal and temporal neocortex. In contrast to AD, approximately 50PERCENT of FTD cases are inherited and linkage of families with FTD to loci on chromosomes 17 (FTDP-17) and 3 has been demonstrated. Mutations in the microtubule-associated protein tau cause most cases of chromosome 17-linked FTD, demonstrating for the first time that tau dysfunction can play a primary role in neurodegeneration. However, tau mutations have been identified in only 10-20percent of familial FTD cases and have not been demonstrated in sporadic FTD. Thus, the etiology of sporadic FTD remains unknown. Association studies have also suggested a role for tau in progressive supranuclear palsy (PSP), with tau mutations reported in two families, confirming previous pathological evidence of tau abnormalities in PSP. The results of linkage disequilibrium studies between tau and Parkinsons disease (PD), AD and other neurodegenerative disorders are more controversial. In this review, we summarize the relevant genetic aspects of FTD and related neurodegenerative disorders, focusing on studies of linkage analysis and tau mutations.
Keywords: Frontotemporal Dementia, Alzheimers Disease, Parksons disease, Progressive supranuclear palsy PSP, Haman dementing illnesses, Frontotemporal dementia FTD, APOE, Non-Alzheimers Dmentias, FTDP-17
Current Genomics
Title: The Genetics of Frontotemporal Dementia and Related Disorders
Volume: 1 Issue: 4
Author(s): M. J. Sobrido, M. Wiedau-Pazos and D. H. Geschwind
Affiliation:
Keywords: Frontotemporal Dementia, Alzheimers Disease, Parksons disease, Progressive supranuclear palsy PSP, Haman dementing illnesses, Frontotemporal dementia FTD, APOE, Non-Alzheimers Dmentias, FTDP-17
Abstract: Recent advances in genetics have revolutionized our understanding of dementia. In the most common of the human dementing illnesses-Alzheimer s disease (AD)- mutations in three major genes causing rare dominantly inherited AD (APP, PS1 and PS2), and other contributory genetic risk factors, such as APOE have been identified. Although neurofibrillary tangles composed of tau protein filaments are a diagnostic feature of AD, tau mutations have not been described in AD. Frontotemporal dementia (FTD) encompasses a group of non-Alzheimers degenerative dementias affecting mainly the frontal and temporal neocortex. In contrast to AD, approximately 50PERCENT of FTD cases are inherited and linkage of families with FTD to loci on chromosomes 17 (FTDP-17) and 3 has been demonstrated. Mutations in the microtubule-associated protein tau cause most cases of chromosome 17-linked FTD, demonstrating for the first time that tau dysfunction can play a primary role in neurodegeneration. However, tau mutations have been identified in only 10-20percent of familial FTD cases and have not been demonstrated in sporadic FTD. Thus, the etiology of sporadic FTD remains unknown. Association studies have also suggested a role for tau in progressive supranuclear palsy (PSP), with tau mutations reported in two families, confirming previous pathological evidence of tau abnormalities in PSP. The results of linkage disequilibrium studies between tau and Parkinsons disease (PD), AD and other neurodegenerative disorders are more controversial. In this review, we summarize the relevant genetic aspects of FTD and related neurodegenerative disorders, focusing on studies of linkage analysis and tau mutations.
Export Options
About this article
Cite this article as:
Sobrido J. M., Wiedau-Pazos M. and Geschwind H. D., The Genetics of Frontotemporal Dementia and Related Disorders, Current Genomics 2000; 1 (4) . https://dx.doi.org/10.2174/1389202003351256
DOI https://dx.doi.org/10.2174/1389202003351256 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association of Platelet Activation with Vascular Cognitive Impairment: Implications in Dementia Development?
Current Vascular Pharmacology Efficacy of Gene Therapy to Restore Cognition in Alzheimer’s Disease: A Systematic Review
Current Gene Therapy Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research The Prevention and Treatment of Delirium in Elderly Patients Following Hip Fracture Surgery
Recent Patents on CNS Drug Discovery (Discontinued) FDG PET/MR Imaging in Major Neurocognitive Disorders
Current Alzheimer Research Editorial (Thematic Issue: From Current Diagnostic Tools and Therapeutics for Alzheimer's Disease Towards Earlier Diagnostic Markers and Treatment Targets)
Current Alzheimer Research Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer’s Disease and Amnestic Mild Cognitive Impairment
Current Alzheimer Research Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry Screening for Inhibitors of Tau Protein Aggregation into Alzheimer Paired Helical Filaments: A Ligand Based Approach Results in Successful Scaffold Hopping
Current Alzheimer Research Therapeutic Potential of Hepatocyte Growth Factor for Treating Neurological Diseases
Current Drug Therapy Possible Role of Vascular Risk Factors in Alzheimer's Disease and Vascular Dementia
Current Pharmaceutical Design Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Nitric Oxide: Target for Therapeutic Strategies in Alzheimers Disease
Current Pharmaceutical Design Evolving Therapeutic Targets in Ischemic Stroke: A Concise Review
Current Drug Targets Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Introduction: Advancing Drug Discovery for Alzheimers Disease [ ISOA Fifth Annual Investigators Meeting “Recent Advances in Drug Discovery and Development for Alzheimers Disease” Sponsored by Elan Pharmaceuticals Inc, The Graphic Expression, Glaxo Smith Kline Pharmaceuticals, Neurochem Inc, Pfizer Inc. (Guest Editors: Howard M. Fillit and Lorenzo M. Refolo)]
Current Alzheimer Research Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders
Current Neurovascular Research Oral GPIIb / IIIa Antagonists: What Went Wrong?
Current Pharmaceutical Design Biomarker Research of Preclinical Alzheimer’s Disease and MCI Based on Neuroimage Techniques
Neuroscience and Biomedical Engineering (Discontinued)